92 related articles for article (PubMed ID: 17929562)
1. [Role of RASSF1A hypermethylation in prostate cancer].
Wang YC; Yu ZH; Chen LB
Zhonghua Nan Ke Xue; 2007 Sep; 13(9):822-5. PubMed ID: 17929562
[TBL] [Abstract][Full Text] [Related]
2. Frequent hypermethylation of the RASSF1A gene in prostate cancer.
Liu L; Yoon JH; Dammann R; Pfeifer GP
Oncogene; 2002 Oct; 21(44):6835-40. PubMed ID: 12360410
[TBL] [Abstract][Full Text] [Related]
3. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer.
Wang Y; Yu Z; Wang T; Zhang J; Hong L; Chen L
Lung Cancer; 2007 May; 56(2):289-94. PubMed ID: 17267069
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.
Bastian PJ; Ellinger J; Wellmann A; Wernert N; Heukamp LC; Müller SC; von Ruecker A
Clin Cancer Res; 2005 Jun; 11(11):4097-106. PubMed ID: 15930345
[TBL] [Abstract][Full Text] [Related]
5. [Methylation of the promoter region of the RASSF1A gene, a candidate tumor suppressor, in primary epithelial tumors].
Loginov VI; Maliukova AV; Seregin IuA; Khodyrev DS; Kazubskaia TP; Ermilova VD; Gar'kavtseva RF; Kiselev LL; Zabarovskiĭ ER; Braga EA
Mol Biol (Mosk); 2004; 38(4):654-67. PubMed ID: 15456137
[TBL] [Abstract][Full Text] [Related]
6. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
[TBL] [Abstract][Full Text] [Related]
7. [Methylation of the putative tumor suppressor gene, RASSF1A, in primary cervical tumors].
Maliukova AV; Loginov VI; Khodyrev DS; Kadyrova EL; Pronina IV; Ivanova TA; Kiselev FL; Zabarovskiĭ NP; Braga EA
Mol Biol (Mosk); 2004; 38(6):1005-13. PubMed ID: 15612586
[TBL] [Abstract][Full Text] [Related]
8. Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma.
Lázcoz P; Muñoz J; Nistal M; Pestaña A; Encío I; Castresana JS
BMC Cancer; 2006 Oct; 6():254. PubMed ID: 17064406
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic inactivation of RASSF1a in uveal melanoma.
Maat W; van der Velden PA; Out-Luiting C; Plug M; Dirks-Mulder A; Jager MJ; Gruis NA
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):486-90. PubMed ID: 17251440
[TBL] [Abstract][Full Text] [Related]
10. The emerging roles of DNA methylation in the clinical management of prostate cancer.
Perry AS; Foley R; Woodson K; Lawler M
Endocr Relat Cancer; 2006 Jun; 13(2):357-77. PubMed ID: 16728568
[TBL] [Abstract][Full Text] [Related]
11. Molecular biomarker in prostate cancer: the role of CpG island hypermethylation.
Bastian PJ; Yegnasubramanian S; Palapattu GS; Rogers CG; Lin X; De Marzo AM; Nelson WG
Eur Urol; 2004 Dec; 46(6):698-708. PubMed ID: 15548435
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of RASSF1C during in vivo tumor growth identifies it as a tumor suppressor gene.
Li J; Wang F; Protopopov A; Malyukova A; Kashuba V; Minna JD; Lerman MI; Klein G; Zabarovsky E
Oncogene; 2004 Aug; 23(35):5941-9. PubMed ID: 15208682
[TBL] [Abstract][Full Text] [Related]
13. [Hypermethylation of promoter region of RAS association domain family gene1A in esophageal squamous cell carcinoma and significance thereof].
Cong DG; Wang SF
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2932-4. PubMed ID: 18261310
[TBL] [Abstract][Full Text] [Related]
14. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
[TBL] [Abstract][Full Text] [Related]
15. Aberrant methylation and reduced expression of RASSF1A in Ewing sarcoma.
Avigad S; Shukla S; Naumov I; Cohen IJ; Ash S; Meller I; Kollender Y; Issakov J; Yaniv I
Pediatr Blood Cancer; 2009 Dec; 53(6):1023-8. PubMed ID: 19637319
[TBL] [Abstract][Full Text] [Related]
16. Adiposity and age are statistically related to enhanced RASSF1A tumor suppressor gene promoter methylation in normal autopsy kidney tissue.
Peters I; Vaske B; Albrecht K; Kuczyk MA; Jonas U; Serth J
Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2526-32. PubMed ID: 18086755
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of RASSF1A promoter methylation in operable breast cancer.
Kioulafa M; Kaklamanis L; Mavroudis D; Georgoulias V; Lianidou ES
Clin Biochem; 2009 Jul; 42(10-11):970-5. PubMed ID: 19374895
[TBL] [Abstract][Full Text] [Related]
18. Aberrant promoter hypermethylation in serum DNA from patients with silicosis.
Umemura S; Fujimoto N; Hiraki A; Gemba K; Takigawa N; Fujiwara K; Fujii M; Umemura H; Satoh M; Tabata M; Ueoka H; Kiura K; Kishimoto T; Tanimoto M
Carcinogenesis; 2008 Sep; 29(9):1845-9. PubMed ID: 18632757
[TBL] [Abstract][Full Text] [Related]
19. Methylation analysis of BRCA1, RASSF1, GSTP1 and EPHB2 promoters in prostate biopsies according to different degrees of malignancy.
Rabiau N; Thiam MO; Satih S; Guy L; Kemeny JL; Boiteux JP; Fontana L; Bignon YJ; Bernard-Gallon D
In Vivo; 2009; 23(3):387-91. PubMed ID: 19454503
[TBL] [Abstract][Full Text] [Related]
20. Gene-specific promoter hypermethylation without global hypomethylation in follicular thyroid cancer.
Lee JJ; Geli J; Larsson C; Wallin G; Karimi M; Zedenius J; Höög A; Foukakis T
Int J Oncol; 2008 Oct; 33(4):861-9. PubMed ID: 18813801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]